[ad_1]
AstraZeneca has been licensed in more than 50 countries, but has not yet been approved in the United States.
In the US, 30,000 people participated in the study. volunteers, of which 20 thousand. was vaccinated and the rest received placebo. The results of the study were published Monday.
The company said in a statement that its vaccine is 79% effective in protecting against COVID-19 symptoms. and it is 100 percent. effective in preventing serious illness and hospitalization.
According to the researchers, the vaccine is effective in all age groups, including the elderly. Previous studies in other countries have failed to establish this.
The preliminary findings from the US study are only part of the information AstraZeneca must provide to the US Food and Drug Administration (FDA). The FDA Advisory Committee will conduct a public discussion on the vaccine data submitted, after which the agency will decide whether to allow use of the product in an emergency.
The researchers eagerly awaited the results of the US study, hoping they would clear up some questions about the effectiveness of these vaccines.
The United Kingdom was the first of the countries to approve the vaccine, based on partial results of clinical trials in Britain, Brazil and South Africa, which showed an efficacy of around 70 percent. However, these results were overshadowed by a manufacturing error that resulted in some participants receiving only half the dose at the first vaccination. Researchers were slow to recognize this error.
Subsequently, more questions arose about whether the vaccine was effective in protecting the elderly and how long after the second vaccination it should be given. Some European countries, including Germany, France and Belgium, initially prevented the vaccine from being used in older people and changed the decision only after new data showed that it was effective in protecting older people.
Last week, more than a dozen lakes, mostly from European countries, stopped vaccinating with AstraZeneca after rare reports of blood clots.
The European Medicines Agency (EMA) said Thursday that it had analyzed the available information and that the AstraZeneca vaccine did not increase the overall risk of blood clots, but could not rule out that it was associated with two extremely rare types of blood clots. .
Following the EEA statement, France, Germany, Italy and other countries resumed vaccination with AstraZeneca on Friday. A string of high-ranking politicians, including Lithuanian President Gitanas Nausėda, Prime Minister Ingrida Šimonytė and Seimas President Viktorija Čmilytė-Nielsen, decided to get vaccinated to show the public that they were confident in their safety.
If you have any questions about the COVID-19 vaccine, please send them to our editorial staff by email. email address [email protected].
[ad_2]
